This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 3 min This content is machine translated Type 1 diabetes Baricitinib helps beta cells Baricitinib, a JAK1 and JAK2 inhibitor, is often used to treat rheumatoid arthritis, alopecia areata or severe coronavirus disease. Doctors in Australia have also investigated whether the drug could preserve…
View Post 9 min This content is machine translated Journal Club: Atopic dermatitis Modern systems therapy – status quo and prospects The therapeutic landscape for atopic dermatitis is changing. New findings have made it possible to develop modern treatment options that selectively target inflammatory signaling pathways. There are currently two modern…
View Post 4 min This content is machine translated "Small Molecules" at AD Current analyses of the pioneer among the JAK-i The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1…
View Post 7 min This content is machine translated Atopic dermatitis: guideline update Current recommendations on biologics and JAK inhibitors With the increasing number of system therapeutics, practical advice on choosing the most suitable treatment option is becoming more important. The new edition of the S3 guideline on atopic dermatitis…
View Post 4 min This content is machine translated System therapy for atopic dermatitis: biologics or JAK inhibitors? Balancing benefits and risks The era of targeted systemic treatment began several years ago and the therapy armamentarium is constantly expanding, so that the question of selection criteria for the individually appropriate therapy is…
View Post 6 min This content is machine translated Atopic eczema EuroGuiDerm guideline – overview of current recommendations for system therapy Recently, there have been significant advances in the treatment of atopic dermatitis, including several new systemic therapeutic options overcoming regulatory hurdles. This has also been incorporated into the EuroGuiDerm guideline…
View Post 6 min This content is machine translated Alopecia areata: drug therapy Which method achieves the best hair growth rates? Alopecia areata (AA) manifests as acute or chronic non-scarring hair loss. Diphenylcyclopropenone and Janus kinase inhibitors have a significantly higher remission rate compared with the spontaneous course, especially in severe…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
View Post 3 min This content is machine translated Atopic dermatitis: JAK inhibitors Baricitinib combined with topical steroids achieves high patient benefit When topical steroid therapy alone is not sufficiently effective, patients with atopic dermatitis may benefit greatly from the additional use of the JAK inhibitor baricitinib. This is shown, among other…
View Post 11 min This content is machine translated Therapy of rheumatoid arthritis Long-term safety for RA patients under JAK inhibition The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of… CME-Test
